It's clearly BASF's strategic thinking not to give in and raise the price unless they get some information that justifies it.
Silke Stegemann
The pain threshold is around 0. They can't go a lot over 0 without the capital markets seeing that negatively. There is a point where a price would not justify the transaction.
pain price
This is a real setback.
real
information thinking price strategic give
This move comes as a surprise, but BASF so far has an excellent track record in acquisitions that were always adding value to investors.
surprise
This is a good amendment of Bayer's cardiology and hematology portfolio.
good
I think Engelhard is opening up to a friendly transaction.
The results were in line. The chemicals cycle is humming right now. The high dividend is not surprising, seeing the growth in profit.
results growth profit
Strengthening their product range further down the value chain makes a lot of sense.
sense
The company's salt acquisitions are paying off big time thanks to the winter weather.
time weather winter big
If the final price comes in over 0 per share, we would consider this negative.
negative share price
You must log in to post a comment.
There are no comments yet.